Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: A total of 795 patients were randomly assigned between May 1999 and April 2001. A median time to progression of 8.7 months, response rate of 45%, and median survival time of 19.5 months were observed for FOLFOX. These results were significantly superior to those observed for IFL for all end points (6.9 months, 31%, and 15.0 months, respectively) or for IROX (6.5 months, 35%, and 17.4 months, respectively) for time to progression and response. The FOLFOX regimen had significantly lower rates of severe nausea, vomiting, diarrhea, febrile neutropenia, and dehydration. Sensory neuropathy and neutropenia were more common with the regimens containing oxaliplatin. CONCLUSION:
|
Authors | Richard M Goldberg, Daniel J Sargent, Roscoe F Morton, Charles S Fuchs, Ramesh K Ramanathan, Stephen K Williamson, Brian P Findlay, Henry C Pitot, Steven R Alberts |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 22
Issue 1
Pg. 23-30
(Jan 01 2004)
ISSN: 0732-183X [Print] United States |
PMID | 14665611
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Organoplatinum Compounds
- Leucovorin
- Fluorouracil
- Camptothecin
|
Topics |
- Adenocarcinoma
(drug therapy, pathology)
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects, therapeutic use)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Colorectal Neoplasms
(drug therapy, pathology)
- Disease Progression
- Female
- Fluorouracil
(administration & dosage, adverse effects)
- Humans
- Infusions, Intravenous
- Injections, Intravenous
- Leucovorin
(administration & dosage, adverse effects)
- Male
- Middle Aged
- Organoplatinum Compounds
(administration & dosage)
- Survival Analysis
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|